Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. [electronic resource]
Producer: 20030501Description: 899-909 p. digitalISSN:- 0896-6273
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- 3,4-Dihydroxyphenylacetic Acid -- analysis
- Animals
- Blotting, Western
- Cell Death
- Clioquinol -- therapeutic use
- Dopamine -- analysis
- Ferritins -- genetics
- Gene Expression
- Genetic Therapy
- Homovanillic Acid -- analysis
- Humans
- Immunohistochemistry
- Iron -- metabolism
- Iron Chelating Agents -- metabolism
- Mice
- Mice, Transgenic
- Oxidative Stress
- Parkinson Disease -- drug therapy
- Parkinson Disease, Secondary -- chemically induced
- Promoter Regions, Genetic
- Rats
- Substantia Nigra -- chemistry
- Tyrosine 3-Monooxygenase -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.